Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Mylan Specialty LP | 28 |
| 2 | Kala Bio Inc | 23 |
| 3 | Nippon Soda Co Ltd | 23 |
| 4 | Resonac Holdings Corp | 22 |
| 5 | Massachusetts Institute of Technology | 21 |
| 6 | Cydex Pharmaceuticals Inc | 16 |
| 7 | Denka Co Ltd | 16 |
| 8 | Wyeth LLC | 16 |
| 9 | Ezaki Glico Co Ltd | 12 |
| 10 | FMC Biopolymer AS | 8 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 620 |
| 2 | A61P | Therapeutic activity (drug indications) | 555 |
| 3 | C07D | Heterocyclic compounds | 180 |
| 4 | C07C | Acyclic and carbocyclic compounds | 71 |
| 5 | C12N | Microorganisms, enzymes | 66 |
| 6 | C05G | 61 | |
| 7 | C07K | Peptides | 60 |
| 8 | Y02A | Climate change adaptation | 60 |
| 9 | C05D | 58 | |
| 10 | C05F | 58 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Endodontics and Root Canal Treatments | 39 |
| 2 | Platelet Disorders and Treatments | 24 |
| 3 | Enzyme function and inhibition | 18 |
| 4 | Peptidase Inhibition and Analysis | 14 |
| 5 | Alkaline Phosphatase Research Studies | 12 |
| 6 | Bacterial Genetics and Biotechnology | 11 |
| 7 | Enzyme Production and Characterization | 11 |
| 8 | Glycosylation and Glycoproteins Research | 11 |
| 9 | RNA and protein synthesis mechanisms | 11 |
| 10 | Bacteriophages and microbial interactions | 10 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Domen Leštan | University of Ljubljana | 36 |
| 2 | Claude F. Meares | University of California, Davis | 34 |
| 3 | Matthias Eiber | Technical University of Munich | 29 |
| 4 | Franklin R. Tay | Augusta University | 24 |
| 5 | Ali Afshar‐Oromieh | Heidelberg University | 22 |
| 6 | Benedikt Kranzbühler | University of Zurich | 7 |
| 7 | Ingvar Bjarnason | MRC Clinical Trials Unit at UCL | 13 |
| 8 | Richard F. Hurrell | ETH Zurich | 13 |
| 9 | David A. Goodwin | Stanford University | 12 |
| 10 | K. Itoh | Showa University | 6 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionFrequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Natrii calcii edetas?
Which companies hold the most patents involving this compound?
What is the overall research coverage for Natrii calcii edetas?
What are the primary research topic areas associated with this compound?
Which patent classifications are most frequently associated with this compound?